Rajvir Rathi is a distinguished agriculturist with gold medal of merit to his credit from the prestigious CCS Haryana Agricultural University Hisar Haryana with major in Agricultural Entomology. Through his interest in agriculture and policy development he contributed in planning, shaping and executing the corporate affairs of Agricultural industry and championed inter and Intra Governmental-Industry association, regulatory and scientific affairs, Public Affairs, corporate communications and Agri- product stewardship spanning over more than two decades. He had been a pioneer in scientific communications on all aspects of agriculture and agri-trade promotion.
Having started his professional career with Bayer, Mr Rathi has played a pivotal role for past twenty-five years in designing, developing and delivering quality output in the areas of sales, new molecule registrations, regulatory approvals, public–private partnerships, etc through collaboration and coordination with various national and state stakeholders. He had been instrumental in setting up functions of impactful linkages between Corporate, Industry and Government Affairs. Over more than two decades, these functions have become an integral and a crucial part of any progressively forward-looking organization.
Over the last decade, Mr Rathi has fostered very impactful linkages among various key agricultural stakeholders. Thoroughly stood the test of time, these linkages have now flourished as the platforms for various Public Private Partnerships, innovations and combined initiatives. His scientific competence speaks volumes as he lead the entire crop biotechnology innovation cycle of a new product from conceptualizing to commercially managing the first product stewardship team in India. He also carefully monitored and prevented value drain of intellectual property in the larger Interest of Indian Agri – Input industry.
Harnessing Investment opportunities in Indian Agriculture /Seed Sector
To fully unlock foreign investment, India needs to address some constraints including Regulatory complexity and delays, Risk toward biotech / GM products, infrastructure gaps, Export rules, germplasm exchange and phytosanitary standards, IP enforcement/infringements and Finance.
